LENZ · LENZ Therapeutics, Inc.
$3.84
+0.00 (+0.00%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$123.01M
Shares
31.42M
Volume · Oct 1
47.49K
Avg daily vol (3M)
852.14K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.84
Open$3.90
Day$3.75–3.90
52W close$3.72–49.05
Avg vol 30d698K
Short int10.6M · 33.8% float · 14.6d
Short vol38%
Last earningsAug 11, 2026
DataJun 2021–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Dec 5, 2026
Est · unconfirmed
· in 9 wks
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$21.48M
Trailing 12 months
Net income (TTM)
−$126.00M
Trailing 12 months
Revenue growth YoY
+9.7%
Year over year
Operating margin
-631.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-93.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$24.21M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.7%
Year over year · more shares
Price change (1Y)
-91.8%
Trailing year
Short interest
33.8%
Latest settlement · 14.6 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. LENZ reported Q2 2026 revenue of $5.5 million, highlighted strong patient persistence with over 60% of ePharmacy patients refilling VIZZ and cohorts tracking to five packs annually, and said July telehealth and national TV launches drove over 45% month-over-month prescription growth while it added a fifth ex-U.S. partnership.
Bullish
- + Over 60% of ePharmacy patients have purchased multiple monthly packs since launch, with Q4 2025 and Q1 2026 cohorts tracking to five packs annually.
- + July telehealth launch and national TV campaign drove over 45% month-over-month total prescription growth across all channels.
- + Added fifth ex-U.S. commercialization partnership with Arrotex for Australia/New Zealand, with nine regulatory submissions under review and milestone payments from Théa and Everest/CORXEL.
- + Over 13,000 unique prescribers since launch with approximately 75% prescribing multiple times, indicating repeat prescribing breadth.
Bearish
- − Q2 net loss widened to $31.9 million ($1.02 per share) versus $14.9 million ($0.53) a year ago on launch-related SG&A of $39.4 million.
- − Retail channel prescription pickup has been 'fairly poor and limited,' limiting visibility into persistence outside ePharmacy.
- − ECP awareness has not consistently translated into recurring prescribing, with discussions often consumer-initiated rather than physician-driven.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
−21%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−59%
trailing
YTD return
−76%
this year
Relative strength
−71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $9 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
33.83% of float · ▼ -2.2% MoM · 14.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
147 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
EPS growth
−22%
Y/Y
Free cash flow
$-70.0M
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $9 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
33.83% of float · ▼ -2.2% MoM · 14.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
147 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $4 · 0%
Range high $49
vs 200-day avg -59%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| packs sold and delivered to the customer | 52,000 | six months ended June 30, 2026 | — |
| unique prescribers | 13,000 | from launch through Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LENZ
this stock
LENZ Therapeutics, Inc.
|
$123.01M | -76.0% | — | — | 33.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LENZ | +2.1% | -26.6% | -58.7% | -26.3% | -76.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +2.8% | -26.7% | -70.8% | -25.7% | -87.8% |